Skip to main content
Erschienen in: Wiener klinische Wochenschrift 15-16/2015

01.08.2015 | case report

War and peace? The oncologic and the palliative care perspective on personalized cancer treatment in a patient with advanced cancer

verfasst von: Eva K. Masel, MD, Sophie Schur, Doris Posch, Dietmar Weixler, Johannes G. Meran, Manuela Schmidinger, Herbert H. Watzke

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 15-16/2015

Einloggen, um Zugang zu erhalten

Summary

Personalized cancer treatment utilizing targeted therapies in a tailored approach is based on tumor and/or patient-specific molecular profiles. Recent clinical trials continue to look for new potential targets in heavily pretreated patients or rare disease entities. Careful selection of patients who may derive benefit from such therapies constitutes a challenge. This case report presents an experimental personalized cancer treatment in an advanced cancer patient and provides a list of issues for discussion: How can we combine treatment goals and simultaneously meet the individual needs in advanced cancer reconciling both perspectives: oncology and palliative care?
Literatur
1.
Zurück zum Zitat Ng PC, Murray SS, Levy S, Venter JC. An agenda for personalized medicine. Nature. 2009;461(7265):724–6.CrossRefPubMed Ng PC, Murray SS, Levy S, Venter JC. An agenda for personalized medicine. Nature. 2009;461(7265):724–6.CrossRefPubMed
2.
Zurück zum Zitat Yanagihara Y, Tanji N, Miura N, Shirato A, Nishimura K, Fukumoto T, et al. Modified FOLFOX6 chemotherapy in patients with metastatic urachal cancer. Chemotherapy. 2013;59(6):402–6.CrossRefPubMed Yanagihara Y, Tanji N, Miura N, Shirato A, Nishimura K, Fukumoto T, et al. Modified FOLFOX6 chemotherapy in patients with metastatic urachal cancer. Chemotherapy. 2013;59(6):402–6.CrossRefPubMed
3.
Zurück zum Zitat Fojo T, Mailankody S, Lo A. Unintended consequences of expensive cancer therapeutics-the pursuit of marginal indications and a me-too mentality that stifles innovation and creativity: the John Conley Lecture. JAMA Otolaryngol Head Neck Surg. 2014;28(10):1225-36.CrossRef Fojo T, Mailankody S, Lo A. Unintended consequences of expensive cancer therapeutics-the pursuit of marginal indications and a me-too mentality that stifles innovation and creativity: the John Conley Lecture. JAMA Otolaryngol Head Neck Surg. 2014;28(10):1225-36.CrossRef
4.
5.
Zurück zum Zitat Oostendorp LJ, Ottevanger PB, van de Wouw AJ, Schoenaker IJ, de Graaf H, van der Graaf WT, et al. Expected survival with and without second-line palliative chemotherapy: who wants to know? Health Expect. 2014;10(10):12275. Oostendorp LJ, Ottevanger PB, van de Wouw AJ, Schoenaker IJ, de Graaf H, van der Graaf WT, et al. Expected survival with and without second-line palliative chemotherapy: who wants to know? Health Expect. 2014;10(10):12275.
6.
Zurück zum Zitat Jones JW, McCullough LB. Extending life or prolonging death: when is enough actually too much? J Vasc Surg. 2014;60(2):521–2.CrossRefPubMed Jones JW, McCullough LB. Extending life or prolonging death: when is enough actually too much? J Vasc Surg. 2014;60(2):521–2.CrossRefPubMed
7.
Zurück zum Zitat Weeks JC, Catalano PJ, Cronin A, Finkelman MD, Mack JW, Keating NL, et al. Patients’ expectations about effects of chemotherapy for advanced cancer. N Engl J Med. 2012;367(17):1616–25.PubMedCentralCrossRefPubMed Weeks JC, Catalano PJ, Cronin A, Finkelman MD, Mack JW, Keating NL, et al. Patients’ expectations about effects of chemotherapy for advanced cancer. N Engl J Med. 2012;367(17):1616–25.PubMedCentralCrossRefPubMed
8.
Zurück zum Zitat Saunders C. The philosophy of terminal cancer care. Ann Acad Med Singapore. 1987;16(1):151–4.PubMed Saunders C. The philosophy of terminal cancer care. Ann Acad Med Singapore. 1987;16(1):151–4.PubMed
9.
Zurück zum Zitat Ellershaw JE, Lakhani M. Best care for the dying patient. BMJ. 2013;347:f4428. doi:10.1136/bmj.f4428.CrossRefPubMed Ellershaw JE, Lakhani M. Best care for the dying patient. BMJ. 2013;347:f4428. doi:10.1136/bmj.f4428.CrossRefPubMed
10.
Zurück zum Zitat Strasser F, Blum D, Bueche D. Invasive palliative interventions: when are they worth it and when are they not? Cancer J. 2010;16(5):483–7.CrossRefPubMed Strasser F, Blum D, Bueche D. Invasive palliative interventions: when are they worth it and when are they not? Cancer J. 2010;16(5):483–7.CrossRefPubMed
12.
Zurück zum Zitat Burki TK. End-of-life discussions are being left too late. Lancet Oncol. 2012;13(3):e94.CrossRef Burki TK. End-of-life discussions are being left too late. Lancet Oncol. 2012;13(3):e94.CrossRef
13.
Zurück zum Zitat Mack JW, Block SD, Nilsson M, Wright A, Trice E, Friedlander R, et al. Measuring therapeutic alliance between oncologists and patients with advanced cancer: the Human Connection Scale. Cancer. 2009;115(14):3302–11.PubMedCentralCrossRefPubMed Mack JW, Block SD, Nilsson M, Wright A, Trice E, Friedlander R, et al. Measuring therapeutic alliance between oncologists and patients with advanced cancer: the Human Connection Scale. Cancer. 2009;115(14):3302–11.PubMedCentralCrossRefPubMed
14.
Zurück zum Zitat Meier DE, Back AL, Morrison RS. The inner life of physicians and care of the seriously ill. JAMA. 2001;286(23):3007–14.CrossRefPubMed Meier DE, Back AL, Morrison RS. The inner life of physicians and care of the seriously ill. JAMA. 2001;286(23):3007–14.CrossRefPubMed
15.
Zurück zum Zitat Smith TJ, Temin S, Alesi ER, Abernethy AP, Balboni TA, Basch EM, et al. American Society of Clinical Oncology provisional clinical opinion: the integration of palliative care into standard oncology care. J Clin Oncol. 2012;30(8):880–7.CrossRefPubMed Smith TJ, Temin S, Alesi ER, Abernethy AP, Balboni TA, Basch EM, et al. American Society of Clinical Oncology provisional clinical opinion: the integration of palliative care into standard oncology care. J Clin Oncol. 2012;30(8):880–7.CrossRefPubMed
16.
Zurück zum Zitat Ellis LM, Bernstein DS, Voest EE, Berlin JD, Sargent D, Cortazar P, et al. American Society of Clinical Oncology perspective: raising the bar for clinical trials by defining clinically meaningful outcomes. J Clin Oncol. 2014;32(12):1277–80.CrossRefPubMed Ellis LM, Bernstein DS, Voest EE, Berlin JD, Sargent D, Cortazar P, et al. American Society of Clinical Oncology perspective: raising the bar for clinical trials by defining clinically meaningful outcomes. J Clin Oncol. 2014;32(12):1277–80.CrossRefPubMed
17.
Zurück zum Zitat Cherny NI, de Vries EG, Emanuel L, Fallowfield L, Francis PA, Gabizon A, et al. Words matter: distinguishing “personalized medicine” and “biologically personalized therapeutics”. J Natl Cancer Inst. 2014. doi:10.1093/jnci/dju321. Cherny NI, de Vries EG, Emanuel L, Fallowfield L, Francis PA, Gabizon A, et al. Words matter: distinguishing “personalized medicine” and “biologically personalized therapeutics”. J Natl Cancer Inst. 2014. doi:10.1093/jnci/dju321.
Metadaten
Titel
War and peace? The oncologic and the palliative care perspective on personalized cancer treatment in a patient with advanced cancer
verfasst von
Eva K. Masel, MD
Sophie Schur
Doris Posch
Dietmar Weixler
Johannes G. Meran
Manuela Schmidinger
Herbert H. Watzke
Publikationsdatum
01.08.2015
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe 15-16/2015
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-015-0803-x

Weitere Artikel der Ausgabe 15-16/2015

Wiener klinische Wochenschrift 15-16/2015 Zur Ausgabe